Skip to Content

Polatuzumab vedotin with R-CHP for patients with diffuse large B-Cell lymphoma

Adding polatuzumab vedotin, an antibody drug, to a treatment regimen together with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) significantly affects progression-free survival in patients with previously untreated diffuse large B-Cell lymphoma.

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top